Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The complex role of estrogens in inflammation.
Episode 40 with Dr. Raj Kapoor on a clinical trial of phenytoin
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
Risk alleles for multiple sclerosis identified by a genomewide study.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
20th Annual Rehabilitation In Multiple Sclerosis (RIMS) Conference
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Nature Medicine Retracts MS Paper With Ghost Data by Former GSK Researcher
Development of oral immunomodulatory agents in the management of multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 4
American Society for Neurochemistry 47th Annual Meeting
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.

Pages